Literature DB >> 5076801

Pulmonary fibrosis following therapy with Melphalan for multiple myeloma.

B W Codling, T M Chakera.   

Abstract

A patient suffering from multiple myeloma developed pulmonary fibrosis, of a type known to be associated wtih busulphan, whilst being treated with Melphalan. The possible role of Melphalan as the causative agent is discussed. Reference is made to other possible aetiological agents and the reasons for their exclusion are discussed.

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5076801      PMCID： PMC477474          DOI： 10.1136/jcp.25.8.668

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  10 in total

1.  DIFFUSE INTERSTITIAL PULMONARY FIBROSIS AFTER BUSULPHAN THERAPY.

Authors:  E LEAKE; W G SMITH
Journal:  Lancet       Date:  1963-08-31       Impact factor: 79.321

2.  Development of radiation pneumonitis. Time and dose factors.

Authors:  F L JENNNINGS; A ARDEN
Journal:  Arch Pathol       Date:  1962-10

3.  MELPHALAN THERAPY IN MYELOMATOSIS.

Authors:  J WALDENSTROEM
Journal:  Br Med J       Date:  1964-04-04

4.  MULTIPLE MYELOMA PRESENTING AS PULMONARY INFILTRATION. REPORT OF A CASE.

Authors:  S GABRIEL
Journal:  Dis Chest       Date:  1965-01

5.  Interstitial pulmonary fibrosis following busulfan therapy.

Authors:  H OLINER; R SCHWARTZ; F RUBIO; W DAMESHEK
Journal:  Am J Med       Date:  1961-07       Impact factor: 4.965

6.  Hexamethonium lung; report of a case associated with pregnancy.

Authors:  F J COCKERSOLE; W W PARK
Journal:  J Obstet Gynaecol Br Emp       Date:  1956-10

7.  Bleomycin-induced interstitial pneumonia in dogs.

Authors:  R W Fleischman; J R Baker; G R Thompson; U H Schaeppi; V R Illievski; D A Cooney; R D Davis
Journal:  Thorax       Date:  1971-11       Impact factor: 9.139

8.  Oxygen alveolopathy in adults.

Authors:  R M Hall; F R Margolin
Journal:  Clin Radiol       Date:  1972-01       Impact factor: 2.350

9.  Pulmonary lesions associated with busulfan therapy of chronic myelogenous leukemia.

Authors:  R H Kirschner; J R Esterly
Journal:  Cancer       Date:  1971-05       Impact factor: 6.860

10.  Busulphan lung.

Authors:  W A Littler; J M Kay; P S Hasleton; D Heath
Journal:  Thorax       Date:  1969-11       Impact factor: 9.139
  10 in total
  8 in total

Review 1.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 2.  Diffuse alveolar damage--the role of oxygen, shock, and related factors. A review.

Authors:  A L Katzenstein; C M Bloor; A A Leibow
Journal:  Am J Pathol       Date:  1976-10       Impact factor: 4.307

3.  Histopathology of the lung after bone marrow transplantation.

Authors:  J P Sloane; M H Depledge; R L Powles; G R Morgenstern; B S Trickey; P J Dady
Journal:  J Clin Pathol       Date:  1983-05       Impact factor: 3.411

4.  Relationship of gold and penicillamine therapy to diffuse interstitial lung disease.

Authors:  D L Scott; G V Bradby; T J Aitman; G C Zaphiropoulos; C F Hawkins
Journal:  Ann Rheum Dis       Date:  1981-04       Impact factor: 19.103

5.  Pulmonary fibrosis following therapy with melphalan: report of two cases.

Authors:  P P Major; S Laurin; P Bettez
Journal:  Can Med Assoc J       Date:  1980-08-09       Impact factor: 8.262

6.  Busulphan lung in childhood.

Authors:  A Oakhill; I D Green; G T Knowlson; A H Cameron; K J Shah; F G Hill; J R Mann
Journal:  J Clin Pathol       Date:  1981-05       Impact factor: 3.411

7.  Pulmonary toxicity of antineoplastic agents.

Authors:  M R Green
Journal:  West J Med       Date:  1977-10

Review 8.  Drug-induced pulmonary fibrosis.

Authors:  I Y Adamson
Journal:  Environ Health Perspect       Date:  1984-04       Impact factor: 9.031
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.